GlaxoSmithKline's investment in products to combat H1N1 and bird flu infections has made it a global leader in the market of pandemic flu treatment. The strategy, which expanded GSK's portfolio from drugs and vaccines to diagnostic tools and medicated face masks, is expected to help the drugmaker sustain revenue as patents of its blockbuster drugs near expiration.

Related Summaries